Go beyond the FDA approval headlines and into the REAL business of psychedelic medicine. While most eyes are on the drug developers, venture capitalist Maria Velkova shares where the smart money is going. The Tabula Rasa Ventures managing partner tells the untold story of the critical infrastructure needed for psychedelics to succeed post-approval, Big Pharma’s recent entry into the space, the maturation of the industry beyond the hype, and the massive commercial hurdles that many are overloo...
All content for Evolving Minds By Pink Elephant is the property of Pink Elephant Team and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Go beyond the FDA approval headlines and into the REAL business of psychedelic medicine. While most eyes are on the drug developers, venture capitalist Maria Velkova shares where the smart money is going. The Tabula Rasa Ventures managing partner tells the untold story of the critical infrastructure needed for psychedelics to succeed post-approval, Big Pharma’s recent entry into the space, the maturation of the industry beyond the hype, and the massive commercial hurdles that many are overloo...
Why Psychedelic Startups Hit a Wall? Ronan Levy on Field Trip’s Rise, Ketamine Clinics & What’s Next
Evolving Minds By Pink Elephant
49 minutes
3 months ago
Why Psychedelic Startups Hit a Wall? Ronan Levy on Field Trip’s Rise, Ketamine Clinics & What’s Next
Today’s guest is Ronan Levy, co-founder and former CEO of Field Trip Health, joins Jason Najum to reflect on the explosive rise and collapse of one of the first public psychedelic therapy companies. #PsychedelicStartups #KetamineClinics #mentalhealthinnovation #mentalhealthpodcast In this raw and insightful conversation, Ronan shares: - How Field Trip raised $100M and listed on the NASDAQ - Why psychedelic therapy clinics are hard to scale - What went wrong with the ketamine cl...
Evolving Minds By Pink Elephant
Go beyond the FDA approval headlines and into the REAL business of psychedelic medicine. While most eyes are on the drug developers, venture capitalist Maria Velkova shares where the smart money is going. The Tabula Rasa Ventures managing partner tells the untold story of the critical infrastructure needed for psychedelics to succeed post-approval, Big Pharma’s recent entry into the space, the maturation of the industry beyond the hype, and the massive commercial hurdles that many are overloo...
